RxDoctor Payments Data

Robert Walters, MD

Internal Medicine · Norfolk, VANPI 1174503890

Payments from drug & device makers

$309in general payments, 2019–2025

Across 8 payments — averaging $38.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$125
  • Johnson & Johnson$75
  • Vifor Pharma, Inc.$23
  • UCB, Inc.$20
  • Astellas Pharma US Inc$19
  • Scilex Pharmaceuticals Inc.$17
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$309 in reported general payments places this provider in the 60th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$94,468
Medicare patients
531
Services billed
746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban723$182,890
TrulicityDulaglutide143$139,516
RexultiBrexpiprazole110$76,771
LinzessLinaclotide85$46,942
JardianceEmpagliflozin149$42,998
XareltoRivaroxaban145$38,120
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$37,542
Breo ElliptaFluticasone/Vilanterol73$31,646
Incruse ElliptaUmeclidinium Bromide77$29,119
XifaxanRifaximin11$13,808
TradjentaLinagliptin55$13,463
Tresiba Flextouch U-100Insulin Degludec41$13,156
NeuproRotigotine14$12,513
Atorvastatin Calcium795$12,120
Lagevrio (Eua)Molnupiravir11$11,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$125$76,771110 claims
Johnson & JohnsonXarelto$75$38,120145 claims
UCB, Inc.Neupro$20$12,51314 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16$10,78230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →